Upload

Loading icon Loading...

This video is unavailable.

Myelofibrosis Study

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to add Mayo Clinic's video to your playlist.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to like Mayo Clinic's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike Mayo Clinic's video.

Loading icon Loading...

Loading icon Loading...

The interactive transcript could not be loaded.

Loading icon Loading...

Loading icon Loading...

Ratings have been disabled for this video.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.

Uploaded on Nov 30, 2010

Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4--7 in Orlando.

Their findings suggest that both drugs, CYT387 and TG101348, effectively reduce spleen size and alleviate constitutional symptoms, major symptoms of this disorder, but that each have unique benefits.

Below, principal researcher Ayalew Tefferi, M.D., and lead investigator Animesh Pardanani, Ph.D., further discuss these studies.

Loading icon Loading...

Loading...
Working...
to add this to Watch Later

Add to